Advice
Following a full submission.
Pioglitazone (Actos), as triple therapy in combination with metformin and a sulphonylurea, is accepted for restricted use within NHS Scotland for the treatment of patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy and where patients are unable or unwilling to take insulin. It should be initiated and monitored only by physicians experienced in the treatment of diabetes mellitus who will be able to identify and manage patients who might benefit.
Download detailed advice54KB (PDF)
Medicine details
- Medicine name:
- pioglitazone 15mg, 30mg and 45mg tablets (Actos® triple therapy)
- SMC ID:
- 354/07
- Indication:
- Type 2 Diabetes Mellitus
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 12 March 2007